company background image
COMB

CombiGene OM:COMBI Stock Report

Last Price

kr7.95

Market Cap

kr157.4m

7D

-10.2%

1Y

15.9%

Updated

22 Sep, 2022

Data

Company Financials
COMBI fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

COMBI Stock Overview

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden.

CombiGene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CombiGene
Historical stock prices
Current Share Pricekr7.95
52 Week Highkr20.05
52 Week Lowkr6.12
Beta1.67
1 Month Change-6.47%
3 Month Change-1.49%
1 Year Change15.89%
3 Year Change-64.67%
5 Year Change-84.41%
Change since IPO-95.56%

Recent News & Updates

Shareholder Returns

COMBISE BiotechsSE Market
7D-10.2%-11.9%-6.1%
1Y15.9%-41.9%-30.4%

Return vs Industry: COMBI exceeded the Swedish Biotechs industry which returned -38.8% over the past year.

Return vs Market: COMBI exceeded the Swedish Market which returned -27.2% over the past year.

Price Volatility

Is COMBI's price volatile compared to industry and market?
COMBI volatility
COMBI Average Weekly Movement8.2%
Biotechs Industry Average Movement8.2%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market4.3%

Stable Share Price: COMBI is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: COMBI's weekly volatility has decreased from 25% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199910Jan Nilssonhttps://www.combigene.com

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies.

CombiGene Fundamentals Summary

How do CombiGene's earnings and revenue compare to its market cap?
COMBI fundamental statistics
Market Capkr157.42m
Earnings (TTM)kr49.05m
Revenue (TTM)kr114.30m

3.2x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COMBI income statement (TTM)
Revenuekr114.30m
Cost of Revenuekr49.06m
Gross Profitkr65.24m
Other Expenseskr16.19m
Earningskr49.05m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 11, 2022

Earnings per share (EPS)2.48
Gross Margin57.08%
Net Profit Margin42.92%
Debt/Equity Ratio0.0%

How did COMBI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is COMBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COMBI?

Other financial metrics that can be useful for relative valuation.

COMBI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA0.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does COMBI's PE Ratio compare to its peers?

COMBI PE Ratio vs Peers
The above table shows the PE ratio for COMBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average37x
PROB Probi
34.2x9.9%kr2.7b
BIOG B BioGaia
32.9x3.8%kr8.1b
VITR Vitrolife
74x27.3%kr25.8b
GX1 genXone
7xn/azł43.8m
COMBI CombiGene
3.2xn/akr157.4m

Price-To-Earnings vs Peers: COMBI is good value based on its Price-To-Earnings Ratio (3.2x) compared to the peer average (37x).


Price to Earnings Ratio vs Industry

How does COMBI's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Earnings vs Industry: COMBI is good value based on its Price-To-Earnings Ratio (3.2x) compared to the European Biotechs industry average (34.5x)


Price to Earnings Ratio vs Fair Ratio

What is COMBI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COMBI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COMBI's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of COMBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COMBI (SEK7.95) is trading below our estimate of fair value (SEK315.79)

Significantly Below Fair Value: COMBI is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is CombiGene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


33.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CombiGene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether CombiGene is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • CombiGene competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has CombiGene performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


10.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: COMBI has high quality earnings.

Growing Profit Margin: COMBI became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: COMBI has become profitable over the past 5 years, growing earnings by 10.9% per year.

Accelerating Growth: COMBI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: COMBI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.8%).


Return on Equity

High ROE: COMBI's Return on Equity (30.6%) is considered high.


Discover strong past performing companies

Financial Health

How is CombiGene's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: COMBI's short term assets (SEK145.2M) exceed its short term liabilities (SEK5.4M).

Long Term Liabilities: COMBI's short term assets (SEK145.2M) exceed its long term liabilities (SEK1,000.0).


Debt to Equity History and Analysis

Debt Level: COMBI is debt free.

Reducing Debt: COMBI had no debt 5 years ago.

Debt Coverage: COMBI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: COMBI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is CombiGene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate COMBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate COMBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if COMBI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COMBI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as COMBI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Jan Nilsson (73 yo)

5.92yrs

Tenure

kr2,338,469

Compensation

Mr. Jan Nilsson serves as Director at Aptahem AB (publ) since 2022. He has been Chief Executive Officer at CombiGene AB (publ) since October 1, 2016 and also served as it's Director since 2020 until May 20...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD210.86K) is about average for companies of similar size in the Swedish market ($USD222.72K).

Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: COMBI's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: COMBI's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 6 shareholders own 4.22% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.47%
Jan Nordqvist
686,429SEK5.5m0%no data
0.35%
Peter Nilsson
68,800SEK547.0k0%no data
0.19%
Jan Nilsson
37,776SEK300.3k0%no data
0.13%
Merab Kokaia
25,500SEK202.7k0%no data
0.075%
David Woldbye
14,882SEK118.3k0%no data
0.0077%
Per Lundin
1,531SEK12.2k0%no data

Company Information

CombiGene AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: CombiGene AB (publ)
  • Ticker: COMBI
  • Exchange: OM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr157.420m
  • Shares outstanding: 19.80m
  • Website: https://www.combigene.com

Number of Employees


Location

  • CombiGene AB (publ)
  • Agavagen 52A
  • Lidingö
  • Stockholm County
  • 181 55
  • Sweden


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
COMBIOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMay 2015
COJ0DB (Deutsche Boerse AG)YesShare CapitalDEEURMay 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/22 00:00
End of Day Share Price2022/09/22 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.